Home › Type 2 Diabetes › Nebraska
Pag-aaral pangklinika para sa Type 2 Diabetes sa Nebraska
14 pag-aaral para sa Type 2 Diabetes ang naghahanap ng mga kalahok sa mga site sa Nebraska.
Mga Lungsod sa Nebraska
Opisyal na teksto ng pag-aaral (English)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Methodist Physicians Clinic, Fremont
- Quality Clinical Research - Omaha, Omaha
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07064473A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
- Bryan Heart, Lincoln
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 55 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06112418A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- University Of Nebraska Medical Center, Omaha
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07595549A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Omaha
- Research Site, Omaha
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07784270Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
- University of Nebraska Medical Center, Omaha
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT07271186A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Research Site, Omaha
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07662213Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
- Velocity Clinical Research, Lincoln, Lincoln
- Velocity Clinical Research, Omaha, Omaha
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07296484A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
- Research Site, Omaha
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07662135AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Methodist Phys. Clinic, Omaha
Nagre-recruitPhase 3
Edad 45 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07797335A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Research Site, Elkhorn
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT07662109Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
- Methodist Physicians Clinic, Fremont
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT07527650HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
- Velocity Clinical Research Norfolk, Norfolk
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 23, 2026 · NCT07546929Blood Markers of Early Pancreas Cancer
- Unversity of Nebraska Medical Center, Omaha
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 pataas · Lahat ng kasarian · Na-update Peb 2, 2026 · NCT03568630SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease
- University of Nebraska Medical Center, Omaha
Nagre-recruit
Edad 19 hanggang 89 · Lahat ng kasarian · Na-update Okt 22, 2025 · NCT06480786Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.